[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"organ-failure-multiple\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:organ-failure-multiple":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,56,79,111,141,171,203,229,250],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":31,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":55},"100602123","icu-background-early-awareness-for-critical-deterioration-100602123",false,"NCT07119411","ICU Background Early Awareness for Critical deterioratiON","ICU Background Early Awareness for Critical deterioratiON (BEACON)","BEACON","Inclusion Criteria:\n\n* admission to intensive care unit\n\nExclusion Criteria:\n\n* age \\\u003C 18 years\n* presence of documented refused general consent form (at database closure)\n* admission for the sole purpose of dying\u002Forgan donation or evaluation of such",true,"ALL","18 Years",{"count":21,"type":22},1962,"ESTIMATED","OBSERVATIONAL","The study will compare ICU sub-units, those with additional support of a clinician awareness system, ICU Beacon, and those receiving the standard of care. The win-ratio composite outcome will be assessed by comparing patients by study group and stratified by APACHE score at admission.",[26,27,28,29,30],"Respiratory Failure","Circulatory Failure","Mortality","Organ Dysfunction","Organ Failure, Multiple",[32,33,34,35,36,37,38,39,40,41,42],"icu","respiratory failure","circulatory failure","early warning system","prevention","prediction","risk prediction","organ failure","multi-organ failure","win-ratio","ICU Beacon","RECRUITING","2026-06-12",{"date":46,"type":47},"2026-06-15","ACTUAL",{"date":49,"type":47},"2025-12-01",{"date":51,"type":22},"2027-11-01",{"name":53,"class":54},"ETH Zurich","OTHER",1,{"id":57,"slug":58,"hasResults":11,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":62,"eligibilityCriteria":63,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":64,"targetDuration":66,"studyType":23,"phases":4,"briefSummary":67,"conditions":68,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":55},"100401074","heterogeneity-of-critical-illness-a-cohort-study-100401074","NCT04502511","Heterogeneity of Critical Illness: a Cohort Study","Heterogeneity of Critical Illness: Exploring New Risk Factors for Severity of Disease in Intensive Care Patients. A Cohort Study","HEALICS","Inclusion Criteria:\n\n* Adults Definition: age ≥18 years.\n* Emergency admission to the ICU Definition: patients who are acutely admitted to the ICU due to acute or unexpected critical illness, either from the emergency department or the ward or transferred from an ICU (or a ward) from another hospital.\n\nExclusion Criteria:\n\n* Planned admission\n* Absence of an invasive arterial or venous line for blood sampling.\n* Any continued cardiopulmonary resuscitation efforts upon admission which limit access to the patient for research activities.\n* Main ICU admission reason chronic (non-invasive) home ventilation\n* Main ICU admission reason normothermic treatment after cardiac arrest\n* Main ICU admission reason ischemic stroke, intracerebral bleeding, or isolated neurotrauma\n* Main ICU admission reason Coronavirus Disease 2019 (COVID-19)\n* Solid organ or hematopoietic stem cell transplant during current hospital admission\n* Strict isolation due to any contagious disease\n* No informed consent",{"count":65,"type":22},5000,"1 Year","Rationale: There is large heterogeneity in disease states of critically ill patients at ICU admittance and there is also large heterogeneity in their disease severity during ICU stay. Still, some patients may show remarkable similarities in disease patterns. There is a lack of understanding of causal mechanisms that lead to divergent outcomes in critically ill patients, and at the same time different diseases may share common underlying, yet unidentified, causal pathways that could explain similarities between different diseases.\n\nObjective: To explore the association between patient characteristics and the severity of organ failure in critically ill patients admitted to the ICU Study design: Prospective cohort study Study population: Adult critically ill patients in the ICU Intervention (if applicable): not applicable Main study parameters\u002Fendpoints: Maximum severity of organ failure observed during ICU stay measured by the maximum SOFA score and quality of life at one year follow-up",[69,30],"Critically Ill","2026-05-21",{"date":72,"type":47},"2026-05-26",{"date":74,"type":47},"2022-01-01",{"date":76,"type":22},"2030-01-01",{"name":78,"class":54},"University Medical Center Groningen",{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":90,"phases":91,"briefSummary":93,"conditions":94,"keywords":96,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":110},"100604987","phase-4-sivelestat-treatment-for-postoperative-organ-protection-in-type-a-aortic-dissection-100604987","NCT07156656","Sivelestat Treatment for Postoperative Organ Protection in Type A Aortic Dissection","Assessment of the Efficacy of Sivelestat Sodium Treatment in Post-operative Organ Dysfunction in Patients With Acute Type A Aortic Dissection (STOP): a Multicenter, Double-blind RCT","STOP","Inclusion Criteria:\n\n1. Age 18-75 years inclusive.\n2. Written informed consent obtained before participation.\n3. Confirmed acute Stanford type A aortic dissection scheduled for surgical repair.\n\nExclusion Criteria:\n\n1. Life expectancy ≤ 48 hours.\n2. Pregnant or lactation.\n3. Severe pre-operative liver dysfunction: Child-Turcotte-Pugh score 10-15.\n4. Severe pre-operative renal dysfunction: acute or chronic kidney injury meeting criteria for renal-replacement therapy.\n5. Confirmed COPD or asthma.\n6. Immunosuppression: long-term or \\> 2 weeks continuous systemic corticosteroids.\n7. Concomitant or anticipated use of immunomodulators (Xue-Bi-Jing injection, thymosin, IVIG).\n8. Medical or psychological condition that would interfere with study participation, assessment, or outcomes.","75 Years",{"count":89,"type":22},236,"INTERVENTIONAL",[92],"PHASE4","The goal of this multicenter, double-blind, randomized controlled trial is to learn if sivelestat sodium (Siv) can protect the organ function in patients suffered operation for acute type A aortic dissection. The main questions it aims to answer are:\n\n* Can the 3-day-treatment of Siv enlarge the Day-0-to-Day-5 drop in the organ-health score (SOFA score)?\n* Can this treatment significantly shrink the area under the SOFA curve from first dose to Day 5?\n* Can this treatment significantly improve the end of patients in 28 days (clinical outcomes)? Researchers will compare drug Siv to a placebo (a look-alike substance that contains no drug) to see if drug Siv works.\n\nParticipants will:\n\n* Take drug Siv or the placebo through vein continuously for 72 hours\n* Receiving regular intensive care in ICU after the operation",[95,30],"Type A Aortic Dissection",[95,97,98,99],"SOFA","Sivelestat Sodium","Multiple Organ Failure","NOT_YET_RECRUITING","2025-08-27",{"date":103,"type":47},"2025-09-05",{"date":105,"type":22},"2025-09-01",{"date":107,"type":22},"2028-09-30",{"name":109,"class":54},"Shanghai Zhongshan Hospital",6,{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":119,"enrollmentInfo":120,"targetDuration":4,"studyType":90,"phases":122,"briefSummary":124,"conditions":125,"keywords":126,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":55},"100506266","impact-of-fourier-transform-infrared-spectroscopy-ftirs-in-icus-100506266","NCT05872152","Impact of Fourier Transform Infrared Spectroscopy (FTIRS) in ICUs","Impact of Fourier Transform Infrared Spectroscopy (FTIRS) on the Diffusion of ESBL Producing Enterobacterales in Intensive Care Units (ICU)","ECLA'IR","Inclusion Criteria:\n\n* Adult patients hospitalized in ICU\n* ESBL-E carrier\n\nExclusion Criteria:\n\n* none","100 Years",{"count":121,"type":22},900,[123],"NA","This study will assess the impact of FTIRS typing on the spread of ESBL-E in intensive care units",[30],[127,128,129,130,131],"multidrug resistant bacteria","outbreak","prevention and infection control","bacterial typing","Fourier transform infrared spectroscopy","2025-07-21",{"date":134,"type":47},"2025-07-24",{"date":136,"type":47},"2024-01-08",{"date":138,"type":22},"2026-09-01",{"name":140,"class":54},"University Hospital, Caen",{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":147,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":90,"phases":151,"briefSummary":152,"conditions":153,"keywords":156,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":55},"100541495","evaluation-of-the-efficiency-of-intermittent-enteral-nutrition-on-multi-organ-failure-from-patients-with-mechanical-ventilation-in-intensive-care-unit-100541495","NCT06330610","Evaluation of the Efficiency of Intermittent Enteral Nutrition on Multi-organ Failure From Patients With Mechanical Ventilation in Intensive Care Unit","Evaluation de l'efficacité du Support Nutritionnel entéral Intermittent Sur la défaillance d'Organes de Patients de réanimation Sous Ventilation assistée ENteral NUTrition - Continue Intermittent","ENNUT-CI","Inclusion Criteria:\n\n* Patient admitted in ICU for less than 48h, with invasive mechanical ventilation predicted for at least 48h, that can undergo nasogastric feeding for 7 days.\n* Patient under vasopressive drugs\n* Adult patients (age ≥ 18 years)\n* Informed person who has read and signed their consent\n\n  * If the patient is unable to sign their consent (emergency situation), the consent will be signed by a trusted person or a family member, and consent to continue the study will be requested subsequently.\n  * If the patient is unable to sign their consent (emergency situation) and no trusted person is present, the patient may be included in the study. In this case, consent to continue the study will be requested from a trusted person as soon as possible, or from the patient if they are able to understand and sign the consent.\n* Affiliation to a social security scheme\n* No current pregnancy: for women of childbearing age, a beta-HCG blood pregnancy test will be performed upon inclusion; for postmenopausal women, a confirmatory diagnosis must be obtained.\n\nExclusion Criteria:\n\n* Contraindication to enteral nutrition and\u002For nasogastric tube insertion: esophageal varices and occlusive syndrome\n* Artificial enteral nutrition that cannot be initiated within 48 hours of intubation\n* Enteral nutrition ongoing for more than one hour at the time of inclusion\n* Need for exclusive or supplemental parenteral nutrition\n* Moribund patient\n* Person deprived of liberty by an administrative or judicial decision or person placed under judicial protection\u002Fguardianship or curatorship\n* Pregnant or breastfeeding woman",{"count":150,"type":22},174,[123],"This study aims to evaluate the efficiency of intermittent enteral nutrition versus continuous enteral nutrition to prevent from organ failures for patients at the acute phase of sepsis shock with mechanical ventilation in ICU.",[154,155,30],"Intermittent Fasting","Septic Shock",[157,158,159,160,161],"Enteral nutrition","Mechanical ventilation","Intermittent fasting","Sepsis shock","Organ failure","2025-06-25",{"date":164,"type":47},"2025-06-29",{"date":166,"type":47},"2024-07-09",{"date":168,"type":22},"2027-10-09",{"name":170,"class":54},"University Hospital, Rouen",{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":177,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":179,"enrollmentInfo":180,"targetDuration":4,"studyType":90,"phases":182,"briefSummary":183,"conditions":184,"keywords":188,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":193,"lastUpdatePostDateStruct":194,"startDateStruct":196,"completionDateStruct":198,"leadSponsor":200,"locationsCount":202},"100327753","phase-4-rectal-indomethacin-as-early-treatment-for-acute-pancreatitis-indomap-trial-100327753","NCT03547232","Rectal Indomethacin as Early Treatment for Acute Pancreatitis (INDOMAP Trial)","Rectal Indomethacin as Early Treatment for Acute Pancreatitis (INDOMAP Trial): Study Protocol for a Multi-center, Double-blinded, Placebo-controlled, Randomized Clinical Trial","INDOMAP","Inclusion Criteria:\n\n* All patients ages 18-80 years with a diagnosis of AP based on at least 2 of the following criteria:\n* Abdominal pain characteristic of AP\n* Serum amylase and\u002For lipase ≥ 3 times the upper limit of normal\n* Characteristic findings of AP on abdominal CT scan will be screened for study enrollment.\n\nExclusion Criteria:\n\n* Onset time \\>24 hours\n* Presence of renal dysfunction (serum creatinine \\> 1.5 \\*normal upper limit)\n* Severe liver dysfunction\n* Active peptic ulcer disease or GI bleeding\n* Pregnancy or breast-feeding\n* Hypersensitivity to NSAIDs\n* New-onset, exacerbation or uncontrolled hypertension\n* Presence of serious cardiovascular events, including severe heart failure, myocardial infarction (MI) and stroke\n* Mental disability\n* Malignancy-associated acute pancreatitis\n* Post-ERCP pancreatitis\n* Informed consent not signed","80 Years",{"count":181,"type":22},1504,[92],"Acute pancreatitis (AP) is an inflammatory condition of the pancreas following the activated pancreatic enzymes induced by varied causes, with or without other organ(s) dysfunction. The production and release of inflammatory factors is generally considered as the key factor of pathogenesis. Non-steroidal anti-inflammatory drugs (NSAIDs) are the most commonly applied agents for inflammatory diseases. A series studies have proved that indomethacin can reduce the risk of post-endoscopic retrograde cholangiopancreatography (ERCP), but high-quality evidence is still lacking in the field of effectiveness of NSAIDs to treat, rather than prevent, other types of AP. Majority of animal experiments showed that NSAIDs had protective effects for organ functions, but the results of several preliminary clinical studies were inconsistent. Randomized controlled trials are eagerly awaited to elucidate its effects on AP.",[185,186,187,30],"Acute Pancreatitis","Complication","Mortality Rate",[189,190,191,192],"Acute pancreatitis","Indomethacin","Prognosis","Organ dysfunction","2025-06-11",{"date":195,"type":47},"2025-06-15",{"date":197,"type":47},"2024-12-01",{"date":199,"type":22},"2028-12-01",{"name":201,"class":54},"Peking Union Medical College Hospital",17,{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":207,"acronym":208,"eligibilityCriteria":209,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":210,"targetDuration":4,"studyType":90,"phases":212,"briefSummary":213,"conditions":214,"keywords":215,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":224,"leadSponsor":226,"locationsCount":55},"100559631","safety-tolerability-and-performance-of-the-nucleocapture-extracorporeal-therapeutic-apheresis-device-in-the-reduction-of-circulating-cfdnanets-in-subjects-with-pancreatitis-100559631","NCT06566638","Safety, Tolerability and Performance of the NucleoCapture Extracorporeal Therapeutic Apheresis Device in the Reduction of Circulating cfDNA\u002FNETs in Subjects With Pancreatitis","NUC-SAP1","Inclusion Criteria:\n\n1. Adult patients aged 18 or over\n2. Acute pancreatitis (following revised Atlanta definition of 2 out of typical pain, serum amylase \\>3x normal range and\u002For CT\u002FMRI imaging consistent with pancreatitis)\n3. Any aetiology\n4. Acute respiratory (PaO2\u002FFiO2 \\\u003C300), cardiovascular (systolic BP \\\u003C90 or any inotropic therapy) or renal failure (serum creatinine \\>170 µmol\u002Fl, or deterioration of \\>50% eGFR if pre-existing renal disease or urine output \\\u003C0.5ml\u002Fkg\u002Fhr for 3 consecutive hours) presenting at any point during the index admission and persistent after 12 h of fluid resuscitation, but for not more than 72 hours\n5. Have provided written informed consent or consent is given by the patient's legally designated representative or an independent physician (if possible, according to local law).\n\n   Exclusion Criteria:\n6. The use of other non-routine extracorporeal treatments such as very high flux renal replacement therapy (\\>60ml\u002Fkg\u002Fh total exchange), use of high cut off filters or other non-routine extracorporeal treatment columns such as Cytosorb, Toramyxcin, etc).\n7. Presence of severe multiple organ failure at the point of enrolment as evidenced by:\n\n   * Severe refractory vasoplegic failure\n\n     * Norepinephrine dose \\> 0.60 μg\u002Fkg\u002Fmin\n     * Use of epinephrine\n   * Concomitant cardiogenic shock, clinically suspected or cardiac index \\\u003C2.2 L\u002Fmin\u002Fm2 if measured\n\n     * Use of dobutamine, epinephrine, phosphodiesterase inhibitors or levosimendan\n   * Coagulopathy as defined by Platelet count \\\u003C50x10\\^9\u002FL\n8. Calculated Plasma Volume greater than 5000ml as determined by the following formula:\n\n   Vplasma = Vblood x (1 - haematocrit)\n\n   Where:\n\n   Vplasma = PV Vblood = an estimation of total blood volume (TBV; according to Nadler's formula, incorporating height, weight and sex).\n\n   A TBV calculator is available at https:\u002F\u002Fwww.omnicalculator.com\u002Fhealth\u002Fblood-volume\n9. Known liver cirrhosis (histologically proven or clinically suspected)\n10. Active bleeding\n11. Known citrate intolerance if citrate is required for therapeutic apheresis\n12. Known heparin allergy if heparin is required for therapeutic apheresis\n13. Known metastatic disease with life expectancy of \\\u003C12 months and ECOG score of at least 2\n14. Known haematological malignancy if not in remission\n15. Known solid organ transplant and concomitant use of immunosuppression\n16. Known long term oxygen therapy or Home oxygen use\n17. Dialysis dependent Chronic Kidney Disease (CKD Stage 5-D)\n18. Planned or impending dialysis\n19. Prior use of cardiopulmonary resuscitation (CPR) in current admission\n20. Requirement for extracorporeal membrane oxygenation (ECMO)\n21. Patient expected to die within 48 hours of admission to ICU\n22. Known allergy to components of NucleoCapture (Sepharose beads and linker histone H1.3)\n23. Pre-existing disease of the exocrine pancreas including chronic pancreatitis, recurrent acute pancreatitis, pancreatic malignancy and\u002For history of pancreatic surgery\n24. Chronic neuromuscular disease affected breathing\n25. Current Participation in another interventional clinical study\n26. Pregnancy (as established by the presence of beta human chorionic gonadotropin in urine or blood)",{"count":211,"type":22},20,[123],"This is a single-centre, randomised-controlled, open-label, feasibility study to assess the safety, tolerability and performance of the NucleoCapture extracorporeal apheresis device in the reduction of circulating cell-free DNA (cfDNA)\u002FNeutrophil Extracellular Traps (NETs) in patients with severe acute pancreatitis.",[185,30],[189,216,217,218,219],"NucleoCapture","Extracorporeal","Apheresis","Neutrophil extracellular traps","2025-03-17",{"date":222,"type":47},"2025-03-20",{"date":49,"type":22},{"date":225,"type":22},"2027-04-01",{"name":227,"class":228},"Liverpool University Hospitals NHS Foundation Trust","OTHER_GOV",{"id":230,"slug":231,"hasResults":11,"nctId":232,"briefTitle":233,"officialTitle":233,"acronym":4,"eligibilityCriteria":234,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":235,"targetDuration":237,"studyType":23,"phases":4,"briefSummary":238,"conditions":239,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":55},"100576146","electronic-archive-of-internal-medicine-for-the-treatment-of-severe-organ-failure-and-liver-transplantation-mitigo-100576146","NCT06781502","Electronic Archive of Internal Medicine for the Treatment of Severe Organ Failure and Liver Transplantation-MITIGO","Inclusion Criteria:\n\n* Diagnosis of acute or chronic liver disease or LT\n* Age ≥ 18 years\n* Obtaining informed consent\n\nExclusion Criteria:\n\n* no one",{"count":236,"type":22},10000,"10 Years","ELECTRONIC ARCHIVE OF INTERNAL MEDICINE FOR THE TREATMENT OF SERIOUS ORGAN FAILURES AND LIVER TRANSPLANTATION",[30,240],"LIVER TRANSPLANTATION","2025-01-13",{"date":243,"type":47},"2025-01-17",{"date":245,"type":47},"2023-10-21",{"date":247,"type":22},"2033-10",{"name":249,"class":54},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",{"id":251,"slug":252,"hasResults":11,"nctId":253,"briefTitle":254,"officialTitle":254,"acronym":4,"eligibilityCriteria":255,"healthyVolunteers":11,"sex":18,"minAge":256,"maxAge":4,"enrollmentInfo":257,"targetDuration":4,"studyType":90,"phases":259,"briefSummary":260,"conditions":261,"keywords":265,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":55},"100550891","the-impact-and-effect-of-traditional-chinese-medicine-treatment-on-organ-failure-in-critically-ill-patients-100550891","NCT06452966","The Impact and Effect of Traditional Chinese Medicine Treatment on Organ Failure in Critically Ill Patients","Inclusion Criteria:\n\n* Age 20 and above\n* Surgical ICU patients\n* The use of Chinese medicine must be approved by the attending physician in the surgical intensive care unit\n\nExclusion criteria:\n\n* Patients' family members refuse TCM intervention","20 Years",{"count":258,"type":22},350,[123],"Critically ill patients are at risk of or suffering from one or more key organs or organ system failure. This study will measure the effect of traditional Chinese medicine(TCM) interventions on critically ill patients admitted to the intensive care unit (ICU).\n\nThe goal of this clinical trial is to learn if traditional Chinese medicine(TCM) is effective for prevention and treatment of organ failure in ICU patients. Patients in this group will receive intervention for 2 weeks.\n\nA multi-center non-randomized real word data study, will include 3 groups: intervention group (TCM)(n=70), control group and historical control group (admitted to the same ICU in the period of 01.2019 to 12.2023).\n\nMain outcomes include sequential organ failure assessment (SOFA) score, ICU length of stay, hospital length of stay, number of days of respirator uses and western medicine medication used study follow up will be 2 weeks.",[30,262,263,26,264],"Indigestion","Delayed Gastric Emptying","Morality",[266,267,268,269],"acupuncture","chinese medicine","Organ Failure","intensive care","2024-06-06",{"date":272,"type":47},"2024-06-11",{"date":274,"type":47},"2024-05-07",{"date":276,"type":22},"2027-05-30",{"name":278,"class":54},"China Medical University Hospital"]